|1.||Pieper, T: 2 articles (03/2001 - 01/2000)|
|2.||Keppler, B K: 2 articles (03/2001 - 01/2000)|
|3.||Küng, A: 1 article (03/2001)|
|4.||Rosenberg, E: 1 article (03/2001)|
|5.||Wissiack, R: 1 article (03/2001)|
|6.||Peti, W: 1 article (01/2000)|
01/01/2000 - "Solvolysis of the Tumor-Inhibiting Ru(III)-Complex trans-Tetrachlorobis(Indazole)Ruthenate(III)."
03/01/2001 - "Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS."
03/01/2001 - "High performance capillary electrophoresis (HPCE) as well as high performance liquid chromatography-mass spectrometry (HPLC-MS) have been applied to the separation, identification and quantification of the tumor-inhibiting ruthenium compounds HIm trans-[RuCl4(im)2] (im = imidazole) and HInd trans-[RuCl4(ind)2] (ind = indazole) and their hydrolysis products. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
01/01/1996 - "Two ruthenium(III) complexes, namely trans-indazolium[tetrachlorobis(indazole)- ruthenate(III)], HInd[RuInd(2)Cl(4)] and trans-imidazolium[tetrachlorobis(imidazole)- ruthenate(III)], HIm[RuIm(2)Cl(4)] exhibit high anticancer activity in an autochthonous colorectal carcinoma model in rats. "